Evidence map›Paper›PMID 36612292›Full record

ArticleCancers2022

High

César Alexander Ortiz Rojas, Abel Costa-Neto, Diego A Pereira-Martins, Duy Minh Le, Dominique Sternadt, Isabel Weinhäuser, Gerwin Huls, Jan Jacob Schuringa, Eduardo Magalhães Rego

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

César Alexander Ortiz RojasDepartment of Medical Images, Hematology and Clinical Oncology, Medical School of Ribeirao Preto, University of São Paulo, Ribeirao Preto 14048-900, Brazil.ORCID 0000-0003-3420-803X
Abel Costa-NetoD'Or Institute for Research and Education (IDOR), São Paulo 04501-000, Brazil.ORCID 0000-0001-9629-3722
Diego A Pereira-MartinsHematology Division, LIM31, Medical School, University of São Paulo, São Paulo 05403-000, Brazil.ORCID 0000-0002-3302-4311
Duy Minh LeDepartment of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
Dominique SternadtDepartment of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
Isabel WeinhäuserHematology Division, LIM31, Medical School, University of São Paulo, São Paulo 05403-000, Brazil.
Gerwin HulsDepartment of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
Jan Jacob SchuringaDepartment of Experimental Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
Eduardo Magalhães RegoCenter for Cell Based Therapy, University of São Paulo, Ribeirao Preto 14051-060, Brazil.ORCID 0000-0003-1567-4086
University Medical Center Groningen · NLUniversidade de São Paulo · BRD’Or Institute for Research and Education · BR

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2013/08135-2Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/08430-5Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/23117-1
6 · The paper itself

Abstract

Several laboratory and clinical variables have been reported to be associated with the outcome of intensive chemotherapy for acute myeloid leukemia (AML), but only a few have been tested in the context of hematopoietic stem cell transplant (HSCT). This study aimed to identify genes whose expression of AML at diagnosis were associated with survival after HSCT. For this purpose, three publicly available adult AML cohorts (TCGA, BeatAML, and HOVON), whose patients were treated with intensive chemotherapy and then subjected to allogeneic or autologous HSCT, were included in this study. After whole transcriptome analysis, we identified

Indexed as

acute myeloid leukemiabiomarkerhematopoietic stem cell transplantationME1prognosis

Identifiers

PMID36612292
PMCPMC9818450
OpenAlexW4313388752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.